Amitriptyline versus placebo in postherpetic neuralgia.

Abstract

To study the effects of amitriptyline in treating postherpetic neuralgia, 24 patients were randomly assigned to either drug or placebo in a double-blind crossover study. We found good to excellent pain relief in 16 of 24 patients (p less than or equal to 0.001). We did not find an antidepressant effect in most patients (p greater than 0.05). The median dose of amitriptyline was 75 mg. The median blood level was 65 ng per milliliter, and of nortriptyline 30 ng per milliliter. Good responses were maintained in 12 of 22 patients. Amitriptyline is useful in treating postherpetic neuralgia and may not act as an antidepressant.

• Authors: C P Watson, R J Evans, K Reed, H Merskey, L Goldsmith, J Warsh
• Journal: Neurology (Neurology) Vol. 32 Issue 6 Pg. 671-3 (Jun 1982) ISSN: 0028-3878 [Print] United States
• PMID: 6283422 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Placebos
• Amitriptyline

Topics

• Aged
• Amitriptyline (blood, therapeutic use)
• Depression (drug therapy)
• Double-Blind Method
• Female
• Herpesviridae Infections (complications, drug therapy)
• Humans
• Male
• Middle Aged
• Neuralgia (drug therapy, etiology)
• Pain (drug therapy)
• Placebos